Sunday , February 25 2018

From the Editor

February, 2018

  • 24 February

    Feb. 24, 2018

    Every week we bring you great information on the latest details of new drugs and new studies on old drugs. In fact in 2018 alone we have had over 20 articles on pharmaceuticals. This plethora of choices and information often overwhelms even the most astute clinician, and when you add …

    Read More »

Latest Articles

February, 2018

Test Your Knowledge

Reducing Heart Risk

According to a recent study, which one of the following diabetes therapies carries a lower risk for adverse cardiovascular (CV) events?

Correct

Correct Answer: 3. CV risk does not differ between these agents

Explanation: Antonios Douros et al. found that the risk for adverse CV events (ie, acute myocardial infarction, ischemic stroke, CV-related death, and all-cause mortality) did not significantly differ between those who used specific, short-acting sulfonylureas vs nonspecific, long-acting agents for type 2 diabetes. However, the nonspecific, long-acting medications were linked to an increased risk for severe hypoglycemia.

Source:

Douros A, et al. Diabetes Care. 2017;40(11):1506-1513.

Incorrect

More Articles

February, 2018

  • 24 February

    The Coming Debate on Closed-Loop Insulin Delivery Systems

    Guest Post by David Kliff, Editor, Diabetic Investor

    As I left Vienna after attending the 11th International Conference on Advanced Technologies & Treatments for Diabetes, my thoughts turned to what does this all mean, what was the most significant takeaway? By far the most significant development coming out of ATTD is the long quest to have a REAL closed-loop insulin delivery system is no longer a pipe dream. This is going to happen and for once I believe it will happen in my lifetime. It is difficult to overstate the power of the data I witnessed. The reality here is that some very smart people have come a very long way.

    Read More »
  • 24 February

    Exercise Offering

    Do you provide any kind of exercise program for your patients? Follow the link to see how you compare to your colleagues.

    Read More »
  • 24 February

    Jim McDermott Current Interview

    Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.

    Read More »
  • 24 February

    Jim McDermott Transcript

    This Exclusive Interview transcript allows you to read the full conversation between Dr. Jim McDermott and Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA. Dr. McDermott discusses the SGLT-2 research at AstraZeneca, including the CVD-REAL  large outcomes trial.

    Read More »
  • 24 February

    Jim McDermott Full Interview

    In this Exclusive Interview, Dr. Jim McDermott talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about AstraZeneca SGLT-2 research, including the CVD-REAL  large outcomes trial.

    Read More »
  • 23 February

    Jim McDermott Part 1, AstraZeneca SGLT2 Trials

    In part 1 of this Exclusive Interview, Dr. Jim McDermott explains the recent AstraZeneca SGLT2 trials in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

    Read More »
  • 23 February

    Jim McDermott Part 2, Efficacy Of SGLT2 Inhibitors

    In part 2 of this Exclusive Interview, Dr. Jim McDermott explains what research shows about the the efficacy of SGLT2 inhibitors and their benefit to risk ratio in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

    Read More »
  • 23 February

    Jim McDermott Part 3, Results From The Duration-8 Study

    In part 3 of this Exclusive Interview, Dr. Jim McDermott explains the DURATION-8 study of Bydureon and dapagliflozin combo therapy in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

    Read More »
  • 23 February

    Jim McDermott Part 4, SGLT2 Effects On Patients

    In part 4 of this Exclusive Interview, Dr. Jim McDermott discusses patient response to the DURATION-8 study, and the continuation of the study in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

    Read More »
  • 23 February

    Jim McDermott Part 5, AstraZeneca DapaCare

    In part 5 of this Exclusive Interview, Dr. Jim McDermott explains DapaCare, the umbrella term that covers AstraZeneca's clinical program with Farxiga (dapagliflozin) in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

    Read More »
  • 23 February

    Jim McDermott Part 6, SGLT2 Cardiovascular Trials

    In part 6, the conclusion of this Exclusive Interview, Dr. Jim McDermott explains SGLT2 cardiovascular trials, including the DECLARE trial that will complete in 2018, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

    Read More »
  • 20 February

    To Give Your Patients Hope, Listen Well to The Stories They Tell Themselves

    I recently met a patient whose life is alternative medicine. Not complementary medicine but alternative medicine. A young woman in her early 30’s who was diagnosed with type 1 diabetes 10 years ago. Besides having an A1C of 10.5%, I could tell she was struggling. Her career is in alternative medicine. For years she has been looking for a way to stop taking insulin. She is looking for the cure, but as with many, has difficulty believing it’s not here yet. She has had diabetes education, but because she hasn’t really met the hcp she can relate to or who has given her the answer she wants to hear, she’s not really put things together yet.

    Read More »
  • 20 February

    Angela Golden Interview 1, Part 1, Patients Over 65 with Obesity

    In part 1 of this 2-part Exclusive Interview, Angela Golden talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin Texas about obesity in people over the age of 65.

    Read More »
  • 20 February

    Framework for Understanding DM Part 9

    In this week's Homerun Slides, practical implementation of the common origins of diabetes and its complications construct.

    Read More »
  • 20 February

    International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #113: Diabetes and Sleep Apnea Part 3

    OSA pathophysiology: OSA is a very complex disorder, and although obesity and fat deposition around the neck plays an important role, there are many other important players that contribute to the development of this condition. The human upper airway is a unique multipurpose structure involved in performing a variety of tasks such as speech, swallowing, and the passage of air for breathing. The airway, therefore, is composed of numerous muscles and soft tissue but lacks rigid or bony support. Most notably, it contains a collapsible portion that extends from the hard palate to the larynx, which allows the upper airway to change shape and momentarily for speech and swallowing during wakefulness; but this feature also provides the opportunity for collapse at inopportune times such as during sleep.

    Read More »